Trevi Therapeutics (TRVI) recently reported that primary results from its Phase 2b CORAL trial of oral nalbuphine ER in idiopathic pulmonary fibrosis chronic cough were published in JAMA, showing statistically significant cough reduction and a safety profile aligned with prior data.

The JAMA publication comes after a mixed period for the stock, with a recent 30 day share price return of 21.01% decline and a year to date share price return of 14.63% decline, yet a very large 1 year total shareholder return of about 2.6x that hints at how data readouts and changing risk perceptions have been influencing sentiment over time.

If Trevi’s IPF cough results have you thinking more broadly about drug development opportunities, it could be worth scanning healthcare stocks for other names pursuing clinically focused growth stories.

With Trevi shares around $10.15 after a 30 day return of a 21.01% decline but a 1 year total return of about 1.6x, is the JAMA backed IPF cough story still underappreciated, or is the market already baking in future growth?

Preferred Price to Book of 6.9x: Is It Justified?

On a P/B of 6.9x at a last close of $10.15, Trevi screens as expensive versus peers and its broader pharmaceuticals group. This sets a high bar for the story behind the stock.

P/B compares the company’s market value to the book value of its net assets, and it is often used for early stage or loss making biopharma names where earnings are not yet meaningful. For Trevi, that 6.9x multiple is being applied to a business that currently reports no revenue and a net loss of $45.858m, so the valuation rests heavily on expectations for future clinical and commercial progress rather than current financial output.

Compared to a peer average P/B of 4.8x, Trevi’s 6.9x suggests investors are paying a premium relative to similar companies. Against the wider US pharmaceuticals industry average of 2.6x, the gap is even wider. That kind of spread points to the market assigning Trevi a higher implied value than both close peers and the sector, rather than lining up with any reference level that the market could move towards.

Result: Price-to-book of 6.9x (OVERVALUED)

However, the story could change quickly if future Haduvio trial readouts disappoint or if Trevi needs to raise fresh capital on less favorable terms.

Build Your Own Trevi Therapeutics Narrative

If you see the numbers differently or want to stress test your own assumptions, you can build a personalized view of Trevi in just a few minutes, starting with Do it your way.

A great starting point for your Trevi Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Trevi has caught your attention, do not stop here. The next step is to scan a wider set of ideas to broaden your perspective.

• Spot early stage opportunities with potential by reviewing these 3514 penny stocks with strong financials that combine smaller market sizes with stronger financial underpinnings.
• Explore future focused themes by checking out these 23 AI penny stocks that are tying artificial intelligence to practical, revenue generating products.
• Search for potential value by combing through these 887 undervalued stocks based on cash flows that appear mispriced based on cash flow expectations and might offer a more attractive entry point.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.